Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HS 10352

Next Previous
X
Search
Drug Profile

HS 10352

Alternative Names: HS-10352

Latest Information Update: 28 Oct 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for phase-I development in Breast-cancer(In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in China (PO)
  • 08 Apr 2022 Pharmacokinetics, efficacy and adverse events data of a phase I trial in Breast cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 12 Jan 2022 Jiangsu Hansoh Pharmaceutical initiates a phase I trial for Breast cancer (Late-stage disease; Combination therapy) in China (PO) (NCT05504213)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top